Brandywine Global Investment Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Brandywine Global Investment Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-17,127	Closed	-$70K	–	894
2019 Q4	$70K	Sell	17,127 -50,142	-75%	-$240K	﹤0.01%	701
2019 Q3	$345K	Sell	67,269 -14,655	-18%	-$90.5K	﹤0.01%	594
2019 Q2	$508K	Buy	81,924 +33,517	+69%	+$193K	﹤0.01%	593
2019 Q1	$345K	Sell	48,407 -5,540	-10%	-$49.8K	﹤0.01%	587
2018 Q4	$461K	Buy	+53,947	New	+$702K	﹤0.01%	569
2017 Q4	–	Sell	-56,283	Closed	-$1.19M	–	953
2017 Q3	$1.19M	Buy	+56,283	New	+$1.03M	0.01%	579

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brandywine Global Investment Management's ADMS Position: Q1 2020 in Review

Brandywine Global Investment Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2020, closing a stake of 17,127 shares — an estimated $70K sold.

Brandywine Global Investment Management first reported a position in ADMS in Q3 2017 and held it in 6 quarters. The position peaked at $1.19M in Q3 2017. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2020.

Brandywine Global Investment Management reported no remaining Adamas Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Brandywine Global Investment Management sold 17,127 Adamas Pharmaceuticals shares in Q1 2020, an estimated $70K.
Brandywine Global Investment Management first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Brandywine Global Investment Management's Adamas Pharmaceuticals position peaked at $1.19M in Q3 2017.
73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2020.

Based on Brandywine Global Investment Management's 13F filing for Q1 2020, filed 15 May 2020.